Arrowhead Pharmaceuticals, Inc. (ARWR) Balance Sheet

As of 2026-06-30 (10-Q), Arrowhead Pharmaceuticals, Inc. (ARWR) reported total assets of $2.1B and shareholders' equity of $465.5M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $54.8M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ARWRArrowhead Pharmaceuticals, Inc.Follow ARWR — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 8.2B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 23 Nov, in 30 days

Line	FY2011 Sep 11	FY2012 Sep 12	FY2013 Sep 13	FY2014 Sep 14	FY2015 Sep 15	FY2016 Sep 16	FY2017 Sep 17	FY2018 Sep 18	FY2019 Sep 19	FY2020 Sep 20	FY2021 Sep 21	FY2022 Sep 22	FY2023 Sep 23	FY2024 Sep 24	FY2025 Sep 25	Latest Jun 26
Cash and equivalents	0.01	0.00	0.02	0.13	0.08	0.09	0.02	0.03	0.22	0.14	0.18	0.11	0.11	0.10	0.23	0.05
Short-term investments	0.00	0.00	0.01	0.02	—	—	—	—	—	0.09	0.13	0.00	0.29	0.58	0.69	1.55
Receivables	—	0.00	0.00	—	—	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.01	0.01
Current assets	0.01	0.01	0.03	0.15	0.10	0.09	0.07	0.08	0.27	0.32	0.38	0.41	0.42	0.70	0.95	1.67
Total assets	0.02	0.02	0.04	0.18	0.13	0.13	0.10	0.11	0.35	0.52	0.71	0.69	0.77	1.14	1.39	2.11
Current liabilities	0.00	0.01	0.01	0.01	0.02	0.03	0.02	0.01	0.10	0.04	0.15	0.14	0.11	0.10	0.20	0.28
Long-term debt	0.00	0.00	0.00	—	—	0.00	0.00	0.00	—	—	—	—	—	—	—	—
Shareholders' equity	0.01	0.01	0.03	0.17	0.11	0.10	0.08	0.10	0.24	0.46	0.41	0.40	0.27	0.19	0.47	0.47

USD billions · SEC XBRL

Arrowhead Pharmaceuticals, Inc. — questions

How much cash does Arrowhead Pharmaceuticals, Inc. have?: $54.8M in cash and cash equivalents as of 2026-06-30.
What are Arrowhead Pharmaceuticals, Inc.'s total assets?: $2.1B as of 2026-06-30.
What is Arrowhead Pharmaceuticals, Inc.'s shareholders' equity?: $465.5M as of 2026-06-30.

Every figure on this page comes from Arrowhead Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.